R&D Q4 Clinical trials round-up: October to December 2025 We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
News J&J's subcutaneous Rybrevant cleared by FDA J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News Datroway filed for TNBC in EU after data delay Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News Padcev/Keytruda scores again in early bladder cancer Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
Oncology ESMO25: Perspective on ‘inside-out oncology’ and targeted al... Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
News Enhertu moves into frontline breast cancer treatment Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.